Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 45.
27. lappuse
... designate the whole group . Typically , the glycosides are composed of three portions : a steroid nucleus , a lactone ring , and a sugar ( hence " glycosides " ) . ( This section should include a chemical and physical description of ...
... designate the whole group . Typically , the glycosides are composed of three portions : a steroid nucleus , a lactone ring , and a sugar ( hence " glycosides " ) . ( This section should include a chemical and physical description of ...
85. lappuse
... designated as ombudsman , whose function shall be to investigate what has happened and to facilitate a timely and equitable resolution . Appro- priate issues to raise with the ombuds- man include resolving difficulties in scheduling ...
... designated as ombudsman , whose function shall be to investigate what has happened and to facilitate a timely and equitable resolution . Appro- priate issues to raise with the ombuds- man include resolving difficulties in scheduling ...
112. lappuse
... designated by the owner to receive the notice . The name and ad- dress of the patent owner or its rep- resentative may be obtained from the United States Patent and Trademark Office ; and ( 2 ) The holder of the approved appli- cation ...
... designated by the owner to receive the notice . The name and ad- dress of the patent owner or its rep- resentative may be obtained from the United States Patent and Trademark Office ; and ( 2 ) The holder of the approved appli- cation ...
137. lappuse
... designated by the owner to receive the notice . The name and ad- dress of the patent owner or its rep- resentative may be obtained from the United States Patent and Trademark Office ; and ( 2 ) The holder of the approved appli- cation ...
... designated by the owner to receive the notice . The name and ad- dress of the patent owner or its rep- resentative may be obtained from the United States Patent and Trademark Office ; and ( 2 ) The holder of the approved appli- cation ...
142. lappuse
... designated by the issuance of an ap- provable or not approvable letter , FDA will provide applicants with an oppor- tunity to meet with agency reviewing officials . The purpose of the meeting will be to discuss what further steps need ...
... designated by the issuance of an ap- provable or not approvable letter , FDA will provide applicants with an oppor- tunity to meet with agency reviewing officials . The purpose of the meeting will be to discuss what further steps need ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning